GMED
GLOBUS MEDICAL INC
Next earnings Aug 5, 2026 · consensus $1.12 EPS, $799M rev
Last earnings -4.7% on 2026-05-07
$80.12
▼ -4.55%$80.12▲ +36.72%
over 1Y
L $51.89H $96.82
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-4.6%
1W-5.4%
1M+2.4%
3M-8.9%
YTD-8.2%
1Y+36.7%
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 21 analysts
Buy
Post-NuVasive synergies are landing — spine leader with 16.7% growth, surging profit, near-zero debt, at a reasonable 20.2x P/E.
Revenue $2.94B · FY2025
The read
Quality fundamentals and an attractive price line up (~86% below fair value) — the rarer case where both the business and the entry look good.
Globus Medical is now a scaled musculoskeletal-implant leader following its NuVasive merger, and FY2025 is the year the integration math finally shows up in the P&L. Revenue grew 16.7% to $2.94B, but the real story is profitability normalizing as merger/integration drag rolls off: net income jumped 422.3% to $538M and operating income rose 189.1% to $480M — off a depressed FY2024 ($103M net income) that was burdened by integration costs. Net margin recovered to 18.3% and operating margin to 16.3%.
The balance sheet is a standout for a medtech company: liabilities/equity of just 0.16x, $4.57B equity, and total liabilities cut 32.1% to $730M. Cash generation is strong and accelerating — operating cash flow grew 44.7% to $753M, funding both $165M of capex (+42.7%, investing in capacity/robotics) and a sharply higher $300M of buybacks (+250.2%, shrinking shares 1.7%). The company is self-funding growth while returning capital, with essentially no financial risk.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:48 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $958M | $1.02B | $1.57B | $2.52B | $2.94B |
| Gross profit | $719M | $759M | $1.02B | — | — |
| Operating income | $172M | $228M | $133M | $166M | $480M |
| Net income | $149M | $190M | $123M | $103M | $538M |
| Diluted EPS | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 |
| Net margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.3B
EV / EBITDA13.7
EV / Sales3.5
EV / FCF17.6
P / FCF18.5
PEG (trailing)0.05
Earnings yield4.9%
FCF yield5.4%
Quality & risk
ROIC (est.)8.3%
Free cash flow$589M
Total debt—
Net cash$526M
Altman Z-Score10.53 safe
Piotroski F-Score8/8
Capital returns
Buyback yield2.8%
Dividend yield (est.)—
Shareholder yield2.8%
Shares Δ YoY-1.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-042026-06-08open ↗144Filing2026-06-05open ↗8-KPeriod ending 2026-06-032026-06-04open ↗SDFiling2026-05-27open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗SCHEDULE 13GFiling2026-04-30open ↗DEFA14AFiling2026-04-24open ↗DEF 14APeriod ending 2026-06-032026-04-24open ↗144Filing2026-04-14open ↗SCHEDULE 13G/AFiling2026-03-26open ↗
Frequently asked
- Is GLOBUS MEDICAL INC (GMED) a buy?
- GMED currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Post-NuVasive synergies are landing — spine leader with 16.7% growth, surging profit, near-zero debt, at a reasonable 20.2x P/E.
- What is GMED's fair value?
- A Modified-Graham model based on GMED's SEC fundamentals estimates a fair value of about $148.96. It is an estimate from reported earnings, not a price target.
- Is GMED overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, GMED currently appears undervalued relative to its SEC-grounded earnings power.
- What is GLOBUS MEDICAL INC's quality score?
- GMED scores 76.38129862453553/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001237831, latest 10-Q filed 2026-05-07) · EODHD · Proprietary analysis · as of 6/21/2026, 8:48:40 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.